*This blog post is my personal opinion only and contains affiliate/referral links.
The biotech buzz is howling, as companies try to bet each other for the right to produce the vaccine that will solve the Covid-19 infection.
Not to downplay the situation, i think the public is looking at these scientists as the saviors who will lead them through the immunity Promise Land.
Although it is still a long way before a wonder drug is distributed, we can find glimpses of hope from the work that they do, and just to highlight a few developments:
The Coalition for Epidemic Preparedness Innovations (CEPI) recently granted a fund to Moderna (MRNA), who along with Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), will conduct a Phase 1 clinical study in the U.S on mRNA-1273 vaccine
With it’s laboratory knowledge on the treatment of Ebola, Regeneron (REGN) is using “the combination of neutralising monoclonal antibodies REGN3048 and REGN3051 is being studied against coronavirus infection in a first-in-human clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The safety and tolerability of the drug will be studied in 48 patients.”
Remdesivir by Gilead Sciences, an ebola drug that was found to be ineffective, is now being tested in two phase III randomised clinical trials in Asian countries. “According to a report by The New England Journal of Medicine (NEJM), Remdesivir, when administered to a coronavirus patient in the US, appeared to have improved the clinical condition.”
It’s no surprise that many companies, even on the micro level, are re-opening and re-directing their projects to respiratory and immunology-related efforts, adding their contribution to the vast knowledge of the mysterious coronavirus.
Companies with high or low market price alike, all are in the forefront of research, that’s why even the latter are benefiting from a spike of interest on the stock market.
For example, Inovio Pharmaceuticals (INO), which received a $5 million grant from the Bill and Mellinda Gates foundation to accelerate the development of the Cellectra® delivery, is standing on its own in the past month of economic turmoil because of it’s investigational DNA immunotherapy, INO-4700. “The vaccine was well-tolerated and demonstrated high immune responses against the MERS-CoV in 94% of patients in the early-stage clinical trial in July 2019.”
Companies with ten or thousand employees alike, everyone is in equal footing in the race; it’s really a matter of time and a lot of clinical trials before a proven vaccine can be perfected.
A look at NASDAQ Biotechnology Index (NBI) in the last month shows a 3822 to 3342 decline. But in the context of all the sell-offs, there’s a surge that can position an investor for a long term gain. There’s a wave of urgency that fuels both the biotech companies and the investing public to hope for a solution, and i think this enthusiasm will create a need for each other economically.
At the history of this sector, it’s probably fair play to say that at this point in time the Biotech Industry is being look upon as a symbol of security in health and also as a sound financial investment.
Whether the vaccine is approved by the end of Summer or next year, we will have more respect to our scientists and we will set a future where we have more infection-fighting immunity drugs to common and pandemic-like diseases.